Navigation Links
Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
Date:8/24/2010

Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back... -- BEIJING, Aug. 24 /PRNewswire-Asia/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals Click to view news release full screen  

Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives

 

BEIJING, Aug. 24 /PRNewswire-Asia/ -- Cellonis Biotechnologies, a Beijing and HK-based medical research and application company, has recorded some remarkable results in the treatment of a twelve-year-old boy with diabetes using their stem cell therapy in a Beijing partner hospital. He has completely regained his normal life, enjoying sports and school activities just like every other person his age, and has been free from injections and drugs for more than half a year.

"Our whole family is delighted with this outcome," his mother commented in a Cellonis interview. "He is now no different from any other child at his school. There is no sign of diabetes anymore. He previously coughed a lot in spring and winter, but after the therapy we haven't seen him coughing at all. We are very pleased."

The boy's doctor during the treatment, Dr. Shi, is similarly satisfied. "The efficacy of our patient's treatment surprised me a lot," she commented. "He hasn't taken insulin injections for eight months, and so does not need to worry about his blood glucose during PE.

"Also, diabetes can stunt a child's growth, with diabetic children being smaller and weaker than other children, but he has grown more than 10cm during this last half year. This is excellent news."

Preventing Dangerous Complications From Diabetes

Diabetes can be especially damaging to children, as it also affects them socially. They have to take care when playing, maintain a healthy diet, and take unpleasant insulin injections daily. Children with diabetes have a much greater risk of complications such as those affecting the kidneys and eyes.

Conventional treatments cannot prevent long-term complications and often have harmful side effects. The Cellonis stem cell therapy is suitable for all ages, with no side effects reported.

"Stem cell treatment is a new hope for diabetes sufferers," Dr. Shi continued. "It can replace dysfunctional pancreatic cells, getting to the root of the disease. Stem cell treatment, both for diabetes and for many other diseases, represents a new age for medicine."

Cellonis Biotechnologies focuses on R&D and the clinical application of personalized stem cell therapies and immunotherapies for patients with diseases including cancer, diabetes and central nervous system disorders.

Urs. J. Lienert COO-International Cellonis Phone: +86-150-1054-7487 Email: ipsc@cellonis.com Web: http://www.diabetescelltreatment.com http://www.cellonis.com
'/>"/>

SOURCE Cellonis Biotechnologies Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
3. UC Riverside researcher develops novel method to grow human embryonic stem cells
4. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System
7. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
8. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
9. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
10. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
11. Trius Awarded $28 Million Contract to Develop Novel Antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):